European_Commission_approves_nintedanibSSc-ILD
Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
Search
InSensitive Content: the impact on dermatologists
Learn about the importance of the dermatology community sharing content related to generalized pustular psoriasis on social media.
InSensitive Content: impact on the GPP patient community
Understand why the patient community should be able to post and consume visual content related to generalized pustular psoriasis.
New partnership to develop schizophrenia treatments
Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments